Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 4 3Phase 2 2Phase NA 1Phase 1/2 1Phase 1 1

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Conditions

Breast Neoplasms 1128Carcinoma, Non-Small-Cell Lung 718Neoplasms 545Prostatic Neoplasms 502Colorectal Neoplasms 438Multiple Myeloma 336Lung Neoplasms 309Neoplasm Metastasis 288Leukemia, Myeloid, Acute 263Stomach Neoplasms 248Carcinoma, Hepatocellular 245Ovarian Neoplasms 225Rectal Neoplasms 211Colonic Neoplasms 204Lymphoma, Follicular 200Lymphoma 199Leukemia 190Uterine Cervical Neoplasms 181Head and Neck Neoplasms 174Pancreatic Neoplasms 171Lymphoma, Non-Hodgkin 167Leukemia, Lymphocytic, Chronic, B-Cell 166Lymphoma, Large B-Cell, Diffuse 163Recurrence 161Melanoma 158Precursor Cell Lymphoblastic Leukemia-Lymphoma 154Squamous Cell Carcinoma of Head and Neck 147Pain 141Urinary Bladder Neoplasms 139Brain Neoplasms 133

Interventions

Fentanyl 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Breakthrough Pain × Clear all
NCT00263575 2024-06-18

Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients

Kyowa Kirin Co., Ltd.

Phase 3 Completed
139 enrolled 7 charts

Neoplasms, Pain, Breakthrough Pain

NCT01326689 2017-03-08

2246-004

Kyowa Kirin Co., Ltd.

Phase 3 Completed
42 enrolled

Cancer Pain, Breakthrough Pain

NCT01842893 2013-05-03

ETHYFYL

Ethypharm

Phase 3 Completed
91 enrolled

Neoplasms, Breakthrough Pain

NCT00236145 2013-01-29

Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 3 Completed

Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡